Orchestra BioMed Shares Jump on FDA Nod for BackBeat Study
19 Settembre 2023 - 4:19PM
Dow Jones News
By Dean Seal
Shares of Orchestra BioMed shot higher after federal regulators
gave it the go-ahead to start a study examining BackBeat, its
atrioventricular interval modulation therapy for treating
hypertension in pacemaker patients.
The stock was up 11.7% at $9.43 in early trading. Shares are
still in negative territory for the year.
The biomedical company said Tuesday that the U.S. Food and Drug
Administration has granted approval of an investigational device
exemption that will allow the study to move forward.
Enrollment is expected to begin before the end of the year.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
September 19, 2023 10:04 ET (14:04 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Orchestra BioMed (NASDAQ:OBIO)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Orchestra BioMed (NASDAQ:OBIO)
Storico
Da Feb 2024 a Feb 2025
